Kura Oncology, Inc. (KURA)
Total Valuation
Kura Oncology has a market cap or net worth of $823.32 million. The enterprise value is $399.15 million.
| Market Cap | 823.32M |
| Enterprise Value | 399.15M |
Important Dates
The next earnings date is Tuesday, May 2, 2023, after market close.
| Estimated Earnings Date | May 2, 2023 |
| Ex-Dividend Date | n/a |
Share Statistics
Kura Oncology has 68.44 million shares outstanding. The number of shares has increased by 0.96% in one year.
| Shares Outstanding | 68.44M |
| Shares Change (YoY) | +0.96% |
| Shares Change (QoQ) | +1.35% |
| Owned by Insiders (%) | 2.75% |
| Owned by Institutions (%) | 106.46% |
| Float | 50.42M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 24.48 |
| PB Ratio | 1.96 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 18.56, with a Debt / Equity ratio of 0.03.
| Current Ratio | 18.56 |
| Quick Ratio | n/a |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
Financial Efficiency
Return on equity (ROE) is -30.80% and return on invested capital (ROIC) is -33.80%.
| Return on Equity (ROE) | -30.80% |
| Return on Assets (ROA) | -29.00% |
| Return on Capital (ROIC) | -33.80% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.07M |
| Employee Count | 127 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -27.12% in the last 52 weeks. The beta is 0.93, so Kura Oncology's price volatility has been similar to the market average.
| Beta (1Y) | 0.93 |
| 52-Week Price Change | -27.12% |
| 50-Day Moving Average | 12.52 |
| 200-Day Moving Average | 14.31 |
| Average Volume (30 Days) | 656,198 |
Short Selling Information
The latest short interest is 7.10 million, so 10.37% of the outstanding shares have been sold short.
| Short Interest | 7.10M |
| Short Previous Month | 7.09M |
| Short % of Shares Out | 10.37% |
| Short % of Float | 14.08% |
| Short Ratio (days to cover) | 10.70 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -139.87M |
| Pretax Income | -135.84M |
| Net Income | -135.84M |
| EBITDA | -134.85M |
| EBIT | -135.61M |
| Earnings Per Share (EPS) | -$2.03 |
Balance Sheet
The company has $438.20 million in cash and $14.02 million in debt, giving a net cash position of $424.17 million or $6.20 per share.
| Cash & Cash Equivalents | 438.20M |
| Total Debt | 14.02M |
| Net Cash | 424.17M |
| Net Cash Per Share | $6.20 |
| Equity / Book Value | 420.28M |
| Book Value Per Share | 6.14 |
| Working Capital | 422.37M |
Cash Flow
In the last 12 months, operating cash flow was -$110.06 million and capital expenditures -$626,000, giving a free cash flow of -$110.69 million.
| Operating Cash Flow | -110.06M |
| Capital Expenditures | -626,000 |
| Free Cash Flow | -110.69M |
| FCF Per Share | -$1.65 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Kura Oncology does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Earnings Yield | -16.50% |
| FCF Yield | -13.44% |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.96% |
| Shareholder Yield | -0.96% |
Analyst Forecast
The average price target for Kura Oncology is $34.17, which is 184.04% higher than the current price. The consensus rating is "Buy".
| Price Target | $34.17 |
| Price Target Difference | 184.04% |
| Analyst Consensus | Buy |
| Analyst Count | 17 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |